Vaccine hope against a sexually transmitted disease: the answer to the burgeoning rise in a superbug
The current study highlights the effect of a meningococcal vaccine on gonorrhoea, a disease caused by a superbug that has evaded vaccine development for over 100 years.
Gonorrhoea is a common bacterial infection caused by a bacteria called Neisseria gonorrhoeae. It is usually sexually transmitted and can cause complications such as an infection of the upper part of the female reproductive system (i.e. pelvic inflammatory disease), septic arthritis and heart muscle inflammation. People can get gonorrhoea over and over again, sometimes several times in a single year: before the discovery of penicillin the disease was untreatable! However, over the years gonorrhoea has become resistant to antibiotics. Recently, strains have emerged that cannot be treated: in this way gonorrhoea has become a superbug.
Interest in a gonorrhoea vaccine extends back over one hundred years and the first vaccine was tested in humans in 1904. Since then just four vaccines have found their way into clinical trials and all failed to protect against the disease. With the absence of a vaccine and antibiotic resistance, the World Health Organization (WHO) indicated that gonorrhoea is a public health priority, and called for action in July 2017.
Until recently the likelihood of discovering an effective gonorrhoea vaccine was low. Many researchers are working on potential vaccine candidates: some of them look encouraging but several years will be necessary before their validation in clinical trials. However, there may have been some clues to potential vaccines staring us in the face for years.
The first clue appeared in Cuba several years ago. Researchers of the Finlay Institute in Havana reported a profound and sustained drop in meningococcal disease as well as gonorrhoea following the widespread use of a meningococcal vaccine, which was subsequently introduced into their infant vaccine schedule in 1991. Actually, there was no concrete proof that the use of the meningococcal vaccine was responsible for such an effect also in gonorrhoea. But the bacteria that cause meningococcal disease and the one causing gonorrhoea are closely related. Both are members of the Neisseria family and they are 80-90% similar in their genes. This provides a biological evidence for the effect of the meningococcal vaccine on gonorrhoea.
Most of the widely used meningococcal vaccines are conjugate vaccines. They are quite purified vaccines in the sense that they contain only selected sugar fragments of the bacterium that our immune system learns to recognize. However, vaccines against the meningococcal group B have been made differently and until very recently only two of them have been widely used. These vaccines are based on vescicles produced by the bacterium, called outer membrane vesicles (OMV); moreover, such vesicles contain many different proteins of great interest to our immune system.
Cuba was not the only country that used a meningococcal OMV vaccine widely. Between 2004 and 2008 New Zealand used a tailor-made OMV vaccine called MeNZB to address a devastating epidemic of meningococcal disease. During a mass immunization campaign over one million people under the age of 20-years were vaccinated.
New Zealand was the only country that had the potential to look more closely at the possible effect of a meningococcal OMV vaccine on gonorrhoea cited before. By collecting all the cases of gonorrhoea and chlamydia (another sexually transmitted infection) from about half of the clinics in New Zealand, our research was able to compare the meningococcal vaccine status between those people with gonorrhoea (cases) and chlamydia (controls). We found that a significantly smaller proportion of people diagnosed with gonorrhoea had been vaccinated compared with people diagnosed with chlamydia. This translated to an effectiveness of the meningococcal OMV vaccine against gnorrhoea of around 31%.
While this may not seem like a very effective vaccine, we must remember that this was not a gonorrhoea vaccine. More research is required to determine the possible effectiveness of other available OMV-containing vaccines such as the new meningococcal B vaccine Bexsero® as well as the Cuban vaccine. Also, investigating the mechanisms behind this effect will be important in order to be able to improve and develop new gonorrhoea-specific vaccines.
Of immediate relevance is that estimates indicate that even a vaccine with an effectiveness of thirty or forty percent, if used well, could reduce the incidence of gonorrhoea dramatically.
Disclosure statement (editorial board): from the original article, Petousis-Harris et al., 2017: "Dr. Helen Petousis-Harris has been a consultant for GlaxoSmithKline (GSK), Merck, and Pfizer but has not received honoraria.The study was supported by GSK Vaccines (formerly known as Novartis Vaccines and Diagnostics, which is now a member of the GSK group of companies after the acquisition by GSK of the non-influenza Novartis Vaccines division), and sponsored by Auckland UniServices."
Original Article:H. Petousis-Harris et al., Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390, 1603-1610 (2017)
Giacomo Rossetti , Review operations
We thought you might like
Fighting back antibiotic resistance: a new hope from the soilFeb 24, 2016 in Microbiology | 4 min read by Dan Kramer
Collateral damage: antibiotics disrupt the balance in the gutJun 2, 2016 in Microbiology | 3.5 min read by Katri Korpela
More from Health & Physiology
City living and psychotic experiences: exploring the role of air pollutionAug 13, 2019 in Health & Physiology | 4 min read by Joanne Newbury , Helen L. Fisher